Table 5. Recommendations regarding treatment monitoring.
| Recommendation | Average value* | Inter-hospital range | P value† |
|---|---|---|---|
| Q8. GOLD 2013. At each visit, determine current smoking status and smoke exposure: | |||
| • Smoking status verified | 591 (95.2) | 72.4–100 | < 0.001 |
| • Pack-years calculated | 558 (89.9) | 68.8–100 | < 0.001 |
| • Both items evaluated | 533 (85.8) | 62.1–100 | < 0.001 |
| Q9. GOLD 2013 recommends monitoring of: | |||
| • Dosages of various medications: ICS dose recorded (n = 397) | 372 (93.7) | 50–100 | < 0.001 |
| • Adherence to the regimen | 327 (52.7) | 3.4–92.6 | < 0.001 |
| • Inhaler technique | Not recorded | ||
| • Effectiveness of the current regime at controlling symptoms: dyspnea recorded | 560 (90.2) | 69.1–100 | < 0.001 |
| • Side effects of treatment | 145 (23.3) | 4.9–66.7 | < 0.001 |
| • All four items recorded | 93 (15.0) | 0–44.4 | < 0.001 |
* Average value expressed as the mean (standard deviation) or absolute (relative) frequency depending on the nature of the variable.
† Calculated for the variability between centers using ANOVA or Chi-square, depending on the nature of the variable. Percentages refer to the whole population (n = 621) unless otherwise indicated. GOLD 2013: Global Initiative for Obstructive Lung Disease 2013 [19]; SEPAR 2009: SEPAR Health-Care Quality Standards 2009 [21]; GesEPOC 2012: Spanish National Guideline for COPD [22].